KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EBT Margin (2016 - 2026)

Bristol Myers Squibb has reported EBT Margin over the past 18 years, most recently at 28.2% for Q1 2026.

  • Quarterly EBT Margin rose 168.0% to 28.2% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 19.79% through Mar 2026, up 697.0% year-over-year, with the annual reading at 19.36% for FY2025, 3670.0% up from the prior year.
  • EBT Margin was 28.2% for Q1 2026 at Bristol Myers Squibb, up from 11.76% in the prior quarter.
  • Over five years, EBT Margin peaked at 28.2% in Q1 2026 and troughed at 97.06% in Q1 2024.
  • The 5-year median for EBT Margin is 16.3% (2022), against an average of 10.44%.
  • Year-over-year, EBT Margin tumbled -12149bps in 2024 and then soared 12358bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 16.3% in 2022, then fell by -11bps to 14.59% in 2023, then crashed by -90bps to 1.42% in 2024, then soared by 729bps to 11.76% in 2025, then soared by 140bps to 28.2% in 2026.
  • Per Business Quant, the three most recent readings for BMY's EBT Margin are 28.2% (Q1 2026), 11.76% (Q4 2025), and 25.48% (Q3 2025).